Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | a51556260ex99_1.htm |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15 (d) of the
Securities Exchange Act of 1934
May
10, 2017
Date
of Report (Date of earliest event reported)
CHARLES RIVER
LABORATORIES INTERNATIONAL, INC.
(Exact
Name of Registrant as specified in its Charter)
______________
Delaware |
001-15943 |
06-1397316 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number)
|
(I.R.S. Employer Identification No.) |
______________
251 Ballardvale Street Wilmington, Massachusetts 01887 |
(Address of Principal Executive Offices) (Zip Code) |
781-222-6000
(Registrant’s
Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company ⃞
If
an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ⃞
ITEM 2.02. Results of Operations and Financial Condition
The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On May 10, 2017, Charles River Laboratories International, Inc. issued a press release providing financial results for the quarter ended April 1, 2017.
The press release, attached as an exhibit to this report, includes "safe
harbor" language pursuant to the Private Securities Litigation Reform
Act of 1995, as amended, indicating that certain statements contained in
the press release are "forward-looking" rather than historic. The press
release also states that these and other risks relating to Charles River
are set forth in the documents filed by Charles River with the
Securities and Exchange Commission.
ITEM 9.01. Financial
Statements and Exhibits
(a) |
Not applicable. |
|
(b) |
Not applicable. |
|
(c) |
Exhibits. |
|
99.1 Press release dated May 10, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
||
|
||
Dated: |
May 10, 2017 |
|
|
||
By: |
/s/ Matthew L. Daniel |
|
Matthew L. Daniel, Corporate Vice President, |
|
|
Deputy General Counsel and Assistant Secretary |
Exhibit Index
Exhibit No. |
Description |
99.1 |
Press release dated May 10, 2017. |
4